MAGE-A4ᶜ¹º³²T for Multi-Tumor | MicrobiomeTrials← Back to trialsNCT03132922
MAGE-A4ᶜ¹º³²T for Multi-Tumor
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2017-05-15Est. Completion: 2022-12-27
Enrollment target: 71 participants Locations- University of Miami, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Washington University, St Louis, Missouri, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina, United States
- Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Tennessee Oncology - Sarah Cannon Research Institute, Nashville, Tennessee, United States
- M.D. Anderson Cancer Center, Houston, Texas, United States
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Other microbiome trials you might be interested in
AdenocarcinomaProstate CancerNeoplasmsCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type
Background:
Prostate cancer is the second most common cause of cancer-related death among men in the United States. Ear…
Bethesda, United StatesEst. completion Jun 15, 2027
Stage IV Bladder Urothelial CarcinomaProstate Cancer
Urothelial Carcinoma
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 an…
Duarte, United StatesEst. completion Dec 31, 2027
Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemot…
Phoenix, United StatesEst. completion Jan 30, 2030